India
· Delayed Price · Currency is INR Rossari Biotech Statistics
Total Valuation
Rossari Biotech has a market cap or net worth of INR 37.64 billion. The enterprise value is 38.64 billion.
| Market Cap | 37.64B |
| Enterprise Value | 38.64B |
Important Dates
The next estimated earnings date is Friday, July 25, 2025.
| Earnings Date | Jul 25, 2025 |
| Ex-Dividend Date | Jun 20, 2025 |
Share Statistics
Rossari Biotech has 55.37 million shares outstanding. The number of shares has increased by 0.08% in one year.
| Current Share Class | 55.37M |
| Shares Outstanding | 55.37M |
| Shares Change (YoY) | +0.08% |
| Shares Change (QoQ) | +0.08% |
| Owned by Insiders (%) | 62.33% |
| Owned by Institutions (%) | 24.94% |
| Float | 17.62M |
Valuation Ratios
The trailing PE ratio is 27.60 and the forward PE ratio is 24.25.
| PE Ratio | 27.60 |
| Forward PE | 24.25 |
| PS Ratio | 1.81 |
| PB Ratio | 3.17 |
| P/TBV Ratio | 4.00 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 27.38 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.14, with an EV/FCF ratio of -183.41.
| EV / Earnings | 28.33 |
| EV / Sales | 1.86 |
| EV / EBITDA | 15.14 |
| EV / EBIT | 20.53 |
| EV / FCF | -183.41 |
Financial Position
The company has a current ratio of 1.94, with a Debt / Equity ratio of 0.18.
| Current Ratio | 1.94 |
| Quick Ratio | 1.10 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | 0.86 |
| Debt / FCF | -10.35 |
| Interest Coverage | 10.51 |
Financial Efficiency
Return on equity (ROE) is 12.21% and return on invested capital (ROIC) is 9.11%.
| Return on Equity (ROE) | 12.21% |
| Return on Assets (ROA) | 6.75% |
| Return on Invested Capital (ROIC) | 9.11% |
| Return on Capital Employed (ROCE) | 13.77% |
| Revenue Per Employee | 38.88M |
| Profits Per Employee | 2.55M |
| Employee Count | 535 |
| Asset Turnover | 1.20 |
| Inventory Turnover | 4.52 |
Taxes
In the past 12 months, Rossari Biotech has paid 488.07 million in taxes.
| Income Tax | 488.07M |
| Effective Tax Rate | 26.36% |
Stock Price Statistics
The stock price has decreased by -5.78% in the last 52 weeks. The beta is 0.26, so Rossari Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.26 |
| 52-Week Price Change | -5.78% |
| 50-Day Moving Average | 674.24 |
| 200-Day Moving Average | 756.06 |
| Relative Strength Index (RSI) | 50.67 |
| Average Volume (20 Days) | 89,705 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Rossari Biotech had revenue of INR 20.80 billion and earned 1.36 billion in profits. Earnings per share was 24.63.
| Revenue | 20.80B |
| Gross Profit | 6.41B |
| Operating Income | 1.87B |
| Pretax Income | 1.85B |
| Net Income | 1.36B |
| EBITDA | 2.49B |
| EBIT | 1.87B |
| Earnings Per Share (EPS) | 24.63 |
Balance Sheet
The company has 1.17 billion in cash and 2.18 billion in debt, giving a net cash position of -1.01 billion or -18.18 per share.
| Cash & Cash Equivalents | 1.17B |
| Total Debt | 2.18B |
| Net Cash | -1.01B |
| Net Cash Per Share | -18.18 |
| Equity (Book Value) | 11.85B |
| Book Value Per Share | 214.12 |
| Working Capital | 5.05B |
Cash Flow
In the last 12 months, operating cash flow was 1.37 billion and capital expenditures -1.59 billion, giving a free cash flow of -210.69 million.
| Operating Cash Flow | 1.37B |
| Capital Expenditures | -1.59B |
| Free Cash Flow | -210.69M |
| FCF Per Share | -3.81 |
Margins
Gross margin is 30.81%, with operating and profit margins of 9.00% and 6.56%.
| Gross Margin | 30.81% |
| Operating Margin | 9.00% |
| Pretax Margin | 8.90% |
| Profit Margin | 6.56% |
| EBITDA Margin | 11.95% |
| EBIT Margin | 9.00% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.50, which amounts to a dividend yield of 0.07%.
| Dividend Per Share | 0.50 |
| Dividend Yield | 0.07% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 2.03% |
| Buyback Yield | -0.08% |
| Shareholder Yield | -0.01% |
| Earnings Yield | 3.62% |
| FCF Yield | -0.56% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Rossari Biotech has an Altman Z-Score of 5.91 and a Piotroski F-Score of 5.
| Altman Z-Score | 5.91 |
| Piotroski F-Score | 5 |